Kurzfassung

This is a prospective, multicenter, multinational, interventional single-armed (management) trial which will determine the safety and efficacy of dabigatran following 72-hour parenteral treatment with low molecular weight heparin in the treatment of patients with acute intermediate-risk PE, and compare its primary efficacy and safety endpoints to the data from recently published phase III trials.